Matinas BioPharma (MTNB) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq drops as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
Matinas BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
March 29, 2021 6:30 AM EDTMatinas to internally focus on its Lipid Nanocrystal (LNC) platform to improve the intracellular delivery of critical therapeutics
Enrollment continues in second patient cohort of EnACT study of MAT2203 in cryptococcal meningitis; Data and Safety Monitoring Board (DSMB) evaluation of safety and efficacy data of key second patient cohort anticipated Q3 2021
Collaboration with National Institute of Allergy and Infectious Disease (NIAID) to formulate Gileads antiviral COVID-19 medication remdesivir has progressed into in vitro studies
Data from ENHANCE-IT study of LYPDISO against Vascepa® support continued development of LYPDISO as a... More
